AREC Stock Overview
A biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Arecor Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.77 |
| 52 Week High | UK£1.99 |
| 52 Week Low | UK£0.63 |
| Beta | -0.27 |
| 11 Month Change | 3.38% |
| 3 Month Change | -15.93% |
| 1 Year Change | -58.87% |
| 33 Year Change | -81.57% |
| 5 Year Change | n/a |
| Change since IPO | -68.39% |
Recent News & Updates
Shareholder Returns
| AREC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.7% | -5.2% | 0.8% |
| 1Y | -58.9% | -20.1% | 6.6% |
Return vs Industry: AREC underperformed the UK Biotechs industry which returned -18.9% over the past year.
Return vs Market: AREC underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| AREC volatility | |
|---|---|
| AREC Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AREC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: AREC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 50 | Sarah Howell | arecor.com |
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products.
Arecor Therapeutics plc Fundamentals Summary
| AREC fundamental statistics | |
|---|---|
| Market cap | UK£28.88m |
| Earnings (TTM) | -UK£8.67m |
| Revenue (TTM) | UK£4.90m |
5.9x
P/S Ratio-3.3x
P/E RatioIs AREC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AREC income statement (TTM) | |
|---|---|
| Revenue | UK£4.90m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£4.90m |
| Other Expenses | UK£13.57m |
| Earnings | -UK£8.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -176.89% |
| Debt/Equity Ratio | 0% |
How did AREC perform over the long term?
See historical performance and comparison